Similarly, several reports have shown that dual PI3K/mTOR inhibitors used as monotherapies mainly lead to cytostatic antitumor effects in lung cancer and other cancers [17, 34], such as pancreatic cancer. Here, MTOR is linked to familial pancreatic carcinoma.